Paratek Pharmaceuticals Announces Second Quarter 2023 Revenue of $40.0 Million

Provided By GlobeNewswire

Last update: Aug 3, 2023

-- NUZYRA^® (omadacycline) Net U.S. Sales of $33.8 Million from the Core Commercial Business, a 35% Increase Over Second Quarter 2022

--Previously Announced Agreement to be Acquired by Gurnet Point Capital and Novo Holdings A/S; Transaction Expected to Close in the Third Quarter